UBS Traders Set for Return to New York Offices at End of June
(Bloomberg) -- UBS Group AG is working on plans to bring back traders and other staff in risk-related roles to its New York locations starting this month, the latest bank to allow key workers to return after the pandemic.
A limited number of employees in jobs that have risk-management aspects will be allowed, but not required, to return to the bank's skyscrapers in the U.S. city, a person familiar with the matter said. The Swiss lender joins rival Morgan Stanley in allowing some employees to return to work after the pandemic's spread eased.
The bank's trading floors in New York are being reconfigured to comply with physical distancing guidelines, the person said. UBS is also considering staggering and assigning departure and arrival times for its staff to avoid lines forming at entry points and elevators, as well as when employees should wear masks and have their temperature checked, according to the person.
“The health and safety of our employees and clients remains of the utmost importance. As we monitor the relaxation of lockdowns across the U.S., we are beginning to prepare our workplaces and our teams for a gradual and safe return to the office,” UBS spokeswoman Erica Chase said. “Our approach will be coordinated across our entire regional footprint, taking into account the relevant local conditions, as well as the guidance of government and public health authorities.”
In Switzerland, UBS workers beyond essential staff will return to offices starting in the middle of the month, with the speed of their return depending on capacity to maintain social distancing.
European peer Barclays Plc is sending 700 employees -- mostly traders -- back to offices in the U.K., U.S. and India starting in July.
Read more:
- Morgan Stanley to Bring Traders Back to NY HQ Next Month: CNBC
- Citi Starts Bringing London Staff Back to Canary Wharf (2)
- Barclays to Return About 700 Staff Globally to Offices (2)
- UBS, Credit Suisse, Commerzbank Are Ramping Up Office Staffing
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.